@entity1162 (LQTS) is a rare but life-threatening disorder affecting cardiac electrophysiology. It occurs due to mutation in genes encoding for the ion channels in ventricular cell membrane. @entity1163 and @entity1167 are the main symptoms of the disease. Anti-adrenergic therapy with oral beta-blockers has been the mainstay of treatment for LQTS. However, up to 30% of @entity1 fail to respond to medical therapy and remain symptomatic. An alarming 10% of @entity1 still experience @entity1167 or @entity1164 during the course of therapy. Left cardiac sympathetic denervation (LCSD) has been used as an alternative therapy in @entity1 who are resistant to beta-blockers. Although LCSD appears effective in reducing the frequency of @entity1163 and improving the survival rate in both the short and long-term, its use has not gained popularity. The recent advent of minimally invasive thoracoscopic sympathectomy may improve the acceptance of LCSD by physicians and @entity1 in the future. The primary objective of this article was to review the current evidence of the clinical efficacy and safety of LCSD in the management of LQTS. The review was based on Medline search of articles published between 1966 and 2002.

Role of left cardiac sympathetic denervation in the management of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1164 :: ('MESH:D016757', 'Disease') :: ['sudden cardiac death'] @entity1163 :: ('MESH:D013575', 'Disease') :: ['syncopal attacks', 'Syncopal attacks'] @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest'] @entity1162 :: ('MESH:D008133', 'Disease') :: ['Congenital long QT syndrome']
@entity1162 :: (MESH:D008133,Disease) :: ['congenital long QT syndrome']
